Douglas W. Beight

1.0k total citations
15 papers, 616 citations indexed

About

Douglas W. Beight is a scholar working on Molecular Biology, Oncology and Organic Chemistry. According to data from OpenAlex, Douglas W. Beight has authored 15 papers receiving a total of 616 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 6 papers in Oncology and 4 papers in Organic Chemistry. Recurrent topics in Douglas W. Beight's work include Chemical Synthesis and Analysis (6 papers), Peptidase Inhibition and Analysis (5 papers) and TGF-β signaling in diseases (3 papers). Douglas W. Beight is often cited by papers focused on Chemical Synthesis and Analysis (6 papers), Peptidase Inhibition and Analysis (5 papers) and TGF-β signaling in diseases (3 papers). Douglas W. Beight collaborates with scholars based in United States. Douglas W. Beight's co-authors include Gary A. Flynn, J. Scott Sawyer, David K. Herron, William T. McMillen, Jonathan M. Yingling, Lei Yan, Edward C. Smith, Faming Zhang, Robert M. Campbell and Bryan D. Anderson and has published in prestigious journals such as Biochemistry, Journal of Medicinal Chemistry and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Douglas W. Beight

15 papers receiving 580 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Douglas W. Beight United States	10	392	210	143	51	42	15	616
Brian L. Batley United States	11	311 0.8×	87 0.4×	150 1.0×	41 0.8×	20 0.5×	18	450
Xiaohong Song China	12	364 0.9×	107 0.5×	100 0.7×	63 1.2×	56 1.3×	22	594
Vincent Bordas United Kingdom	8	511 1.3×	125 0.6×	280 2.0×	48 0.9×	25 0.6×	14	836
Marcel Koenig United States	11	281 0.7×	150 0.7×	121 0.8×	38 0.7×	47 1.1×	17	500
Moorthy S. S. Palanki United States	18	441 1.1×	110 0.5×	297 2.1×	118 2.3×	21 0.5×	28	818
Enrique Poradosu United States	10	308 0.8×	135 0.6×	86 0.6×	39 0.8×	50 1.2×	17	556
Ji Ma China	16	197 0.5×	166 0.8×	104 0.7×	39 0.8×	51 1.2×	40	620
William T. McMillen United States	9	412 1.1×	212 1.0×	95 0.7×	50 1.0×	57 1.4×	15	585
Leonard C. Weir United States	7	232 0.6×	122 0.6×	149 1.0×	31 0.6×	21 0.5×	8	418
Tony C. Luu United States	5	218 0.6×	111 0.5×	157 1.1×	69 1.4×	34 0.8×	5	470

Countries citing papers authored by Douglas W. Beight

Since Specialization

Citations

This map shows the geographic impact of Douglas W. Beight's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Douglas W. Beight with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Douglas W. Beight more than expected).

Fields of papers citing papers by Douglas W. Beight

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Douglas W. Beight. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Douglas W. Beight. The network helps show where Douglas W. Beight may publish in the future.

Co-authorship network of co-authors of Douglas W. Beight

This figure shows the co-authorship network connecting the top 25 collaborators of Douglas W. Beight. A scholar is included among the top collaborators of Douglas W. Beight based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Douglas W. Beight. Douglas W. Beight is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Gifford‐Moore, Donetta S., et al.. (2005). Inhibition of thrombin activatable fibrinolysis inhibitor by cysteine derivatives. Thrombosis Research. 116(3). 265–271. 11 indexed citations

Peng, Sheng-Bin, Lei Yan, Xiaoling Xia, et al.. (2005). Kinetic Characterization of Novel Pyrazole TGF-β Receptor I Kinase Inhibitors and Their Blockade of the Epithelial−Mesenchymal Transition. Biochemistry. 44(7). 2293–2304. 80 indexed citations

Sawyer, J. Scott, et al.. (2005). Carbocyclic[g]indole Inhibitors of Human Nonpancreatic s-PLA₂. Journal of Medicinal Chemistry. 48(3). 893–896. 13 indexed citations

Sawyer, J. Scott, Douglas W. Beight, Bryan D. Anderson, et al.. (2004). Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-β type I receptor kinase domain. Bioorganic & Medicinal Chemistry Letters. 14(13). 3581–3584. 141 indexed citations

Sawyer, J. Scott, Bryan D. Anderson, Douglas W. Beight, et al.. (2003). Synthesis and Activity of New Aryl- and Heteroaryl-Substituted Pyrazole Inhibitors of the Transforming Growth Factor-β Type I Receptor Kinase Domain. Journal of Medicinal Chemistry. 46(19). 3953–3956. 197 indexed citations

Yee, Ying K., Douglas W. Beight, Trelia J. Craft, et al.. (2000). N²-Aroylanthranilamide Inhibitors of Human Factor Xa. Journal of Medicinal Chemistry. 43(5). 873–882. 35 indexed citations

Beight, Douglas W., Shujaath Mehdi, Jack R. Koehl, & Gary A. Flynn. (1996). Synthesis of constrained thiorphan analogs as inhibitors of neutral endopeptidase. Bioorganic & Medicinal Chemistry Letters. 6(17). 2053–2058. 2 indexed citations

Flynn, Gary A., Douglas W. Beight, Shujaath Mehdi, et al.. (1993). Application of a conformationally restricted Phe-Leu dipeptide mimetic to the design of a combined inhibitor of angiotensin I-converting enzyme and neutral endopeptidase 24.11. Journal of Medicinal Chemistry. 36(16). 2420–2423. 53 indexed citations

Flynn, Gary A., Douglas W. Beight, Edward W. Huber, & Philippe Bey. (1990). The conversion of a diazolactam to an α-methylenelactam: An entrance to new conformationally restricted inhibitors of angiotensin-converting enzyme. Tetrahedron Letters. 31(6). 815–818. 7 indexed citations

10.

Giroux, Eugène L., Douglas W. Beight, Richard C. Dage, & Gary A. Flynn. (1989). Interaction of Angiotensin I-Converting Enzyme with Two Potent Tricyclic Inhibitors. Journal of enzyme inhibition. 2(4). 269–277. 4 indexed citations

11.

Flynn, Gary A. & Douglas W. Beight. (1988). “An efficient synthesis of ethyl (R)-2-hydroxy-4-phenylbutyrate: A useful intermediate in the synthesis of converting enzymeinhibitors”. Tetrahedron Letters. 29(4). 423–426. 10 indexed citations

12.

Flynn, Gary A., et al.. (1985). The synthesis of fluorinated aminophosphonic acid inhibitors of alanine racemase. Tetrahedron Letters. 26(3). 285–288. 37 indexed citations

13.

Flynn, Gary A., et al.. (1984). Synthesis of protected 4-demethoxy-8-nordaunomycinone. The Journal of Organic Chemistry. 49(12). 2252–2258. 7 indexed citations

14.

Flynn, Gary A. & Douglas W. Beight. (1984). A dehydroalanine route to an activated phenolic sparsomycin analog. Tetrahedron Letters. 25(25). 2655–2658. 12 indexed citations

15.

Ash, Ronald J., et al.. (1984). Importance of the hydrophobic sulfoxide substituent on nontoxic analogs of sparsomycin. Antimicrobial Agents and Chemotherapy. 25(4). 443–445. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact